What is the Tympanic Membrane Healing Time After Insertion of a Gelfoam PE Tube?

Sponsor
Skovlund Medical Products, LLC (Other)
Overall Status
Completed
CT.gov ID
NCT04902963
Collaborator
(none)
14
1
7.6

Study Details

Study Description

Brief Summary

Pilot study done to evaluate the breakdown and and potential utility of a bioabsorbable ventilation ear tube made with gelatin.

Condition or Disease Intervention/Treatment Phase
  • Device: PE tube
N/A

Detailed Description

Institutional Review Board- Park Nicollet Institute approval was granted 3/2011 for 15 patients to be enrolled in pilot study of use of a bioabsorbable ventilation ear (PE) tube. IRB stated compliance with FDA as defined in 21 CFR, Part 56 and with regulations of DHHS. Federal assurance number FWA00000914. Prior to commencing this study, IRB approval was obtained and each participating clinician completed the NIH training for "Protecting Human Research Participants".

14 patients (15 ears) were enrolled in this study and were examined by 2 independent examiners at approximately 3, 6 and 12 week follow-ups. Lumen patency and time to complete resorption were documented by each examiner. There were no adverse reactions. This pilot study suggests that there is utility for a bioabsorbable ear tube made from gelatin material, as the device was found to break down over the expected time frame and remained functional long enough to have clinical utility.

Study Design

Study Type:
Interventional
Actual Enrollment :
14 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
14 patients underwent placement of a novel absorbable ventilation tube to test utility of this prototype device and monitor resorption over a period of weeks. 14 participants were approved for this study of feasibility to allow for patients who did not follow up per the study protocol.14 patients underwent placement of a novel absorbable ventilation tube to test utility of this prototype device and monitor resorption over a period of weeks. 14 participants were approved for this study of feasibility to allow for patients who did not follow up per the study protocol.
Masking:
None (Open Label)
Masking Description:
2 examiners used otomicroscopy to document the function of the ear tube by documenting the number of weeks the lumen remained patent and the number of weeks until the device was fully resorbed. All examiners documented results independent of the other examiner.
Primary Purpose:
Device Feasibility
Official Title:
What is the Tympanic Membrane Healing Time After Insertion of a Gelfoam PE Tube?
Actual Study Start Date :
Mar 15, 2011
Actual Primary Completion Date :
Nov 1, 2011
Actual Study Completion Date :
Nov 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Experimental: Meeting indication for short term ventilation tube placement

Adult patients meeting standard criteria for short-term ventilation tube placement were offered placement of a bioabsorbable ear tube in place of a durable ear tube that would later be removed.

Device: PE tube
Gelatin mixed with antibiotic and steroid ear drop to create a rigid device that maintains a lumen, acting as an intermediate-duration bioabsorbable ear tube.

Outcome Measures

Primary Outcome Measures

  1. Number of weeks that ventilation tube lumen is patent. [0-3 months]

    Primary outcome was presence of a lumen, reflecting a functional device.

Secondary Outcome Measures

  1. Number of weeks until ventilation tube is fully resorbed. [0-3 months]

    Gelatin has been used in this site as packing material and has been shown to resorb over a period of several weeks. Full resorption of this device is expected.

Eligibility Criteria

Criteria

Ages Eligible for Study:
26 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • meeting indications for placement of a short or intermediate-duration ventilation ear tube (PE tube)
Exclusion Criteria:
  • none

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Skovlund Medical Products, LLC

Investigators

  • Study Director: Tiffany Walker, Park Nicollet Institute, IRB Administrator

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sandra Skovlund, Primary Investigator, Skovlund Medical Products, LLC
ClinicalTrials.gov Identifier:
NCT04902963
Other Study ID Numbers:
  • 04053-10-C
First Posted:
May 26, 2021
Last Update Posted:
May 26, 2021
Last Verified:
May 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 26, 2021